The Technical Analyst
Altamira Therapeutics [CYTO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Altamira Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.23% $1.650
America/New_York / 6 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.70 mill |
| EPS: | -16.15 |
| P/E: | -0.100 |
| Earnings Date: | Apr 10, 2024 |
| SharesOutstanding: | 2.24 mill |
| Avg Daily Volume: | 1.247 mill |
| RATING 2024-05-06 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.164 (-29.45%) $-0.486 |
| Date: 2024-05-06 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.408 - 1.892 ( +/- 14.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2008-05-08 | Carter Stephen | Sell | 10 000 | Common Stock |
| 2008-05-08 | Lokay Kevin G | Sell | 185 439 | Common Stock |
| 2008-05-08 | Lokay Kevin G | Sell | 100 000 | Options to Purchase Common Stock |
| 2008-05-08 | Mollica Joseph A | Sell | 10 000 | Common Stock |
| 2007-11-13 | Lokay Kevin G | Buy | 500 000 | Options to purchase Common Stock par value $0.01 |
| INSIDER POWER |
|---|
| 0.00 |
| Last 33 transactions |
| Buy: 1 218 228 | Sell: 315 439 |
Forecast:
16:00 - $1.650
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.650
Forecast 2: 16:00 - $1.650
Forecast 3: 16:00 - $1.650
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.650 (1.23% ) |
| Volume | 0.0370 mill |
| Avg. Vol. | 1.247 mill |
| % of Avg. Vol | 2.97 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CYTO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | buy | $1.860 | N/A | Active |
|---|
CYTO
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Latest Press Releases
2024-05-01 08:47:00 - Press Release
Altamira Therapeutics Announces Filing Of Provisional Patent Application For Oligophore Nanoparticles With Sirna Targeting P65 Protein In Treatment Of Cancer And Inflammation
Hamilton, bermuda, may 01, 2024 (globe newswire) -- hamilton, bermuda / may 1, 2024 / altamira therapeutics ltd. (“altamira” or the “company”) (nasdaq:cyto), a company dedicated to developing and commercializing rna delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the united states patent office (uspto) which covers nanoparticles comprising the company's oligophore™ platform and sirna targeting the p65 protein, a component of the nf-Κb transcription factor.
2024-04-24 08:47:00 - Press Release
Altamira Therapeutics Announces Publication Of Positive Results From Bentrio Trial In Seasonal Allergic Rhinitis In Top Peer Reviewed Journal
Hamilton, bermuda, april 24, 2024 (globe newswire) -- hamil ton, bermuda -- april 24 , 2024 -- altamira therapeutics ltd. (“altamira” or the “company”) (nasdaq:cyto), a company dedicated to developing and commercializing rna delivery technology for targets beyond the liver, today announced the publication of the detailed results from the nasar clinical trial with bentrio® nasal spray in seasonal allergic rhinitis (sar). the peer-reviewed article appeared in allergy,1 which is published by the european academy of allergy and clinical immunology and recognizes as one of the highest-ranking journals in the field of allergology. bentrio (am-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites.
2024-04-04 08:45:00 - Press Release
Altamira Therapeutics To Host Full Year 2023 Financial Results And Business Update Call On April 10, 2024
Hamilton, bermuda, april 04, 2024 (globe newswire) -- altamira therapeutics ltd. ("altamira" or the "company") (nasdaq: cyto), a company providing nanoparticle-based technology for efficient rna delivery to extrahepatic targets, today announced that it will host its full year 2023 financial results and business update call on friday, april 10, 2024. founder, chairman, and ceo thomas meyer and coo covadonga paÑeda will deliver prepared remarks followed by a q&a session where they will address questions from investors and analysts.
2024-03-25 08:47:00 - Press Release
Altamira Therapeutics Announces Collaboration With Univercells Group On Nanoparticle-delivered Mrna Vaccines
Hamilton, bermuda, march 25, 2024 (globe newswire) -- altamira therapeutics ltd. (“altamira” or the “company”) (nasdaq:cyto), a company providing nanoparticle-based technology for efficient rna delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with univercells group (“univercells”) to evaluate the use of the company's proprietary semaphore platform for the delivery of mrna vaccines. univercells is a global life sciences company creating platforms for developing and manufacturing biologics, including mrna vaccines and therapeutics, in a simple, scalable and cost-efficient way.
2024-02-07 08:47:00 - Press Release
Altamira Therapeutics' Peptide-based Delivery Platform Shown To Enhance Potency Of Commonly Used Gene Delivery Method As Published In Peer-reviewed Journal
Hamilton, bermuda, feb. 07, 2024 (globe newswire) -- independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (aav) vectors, commonly used in gene therapy, when integrating altamira's peptide-based delivery technology increased potency may help to reduce aav immunogenicity and resistance to aavs in certain cell types hamilton, bermuda, feb. 7, 2024 -- altamira therapeutics ltd. (nasdaq: cyto) ("altamira" or the "company"), a company providing nanoparticle-based technology for efficient rna delivery to extrahepatic targets, announced today the publication of a peer-reviewed article in the journal of integrative medicine titled, "melittin analog p5rhh enhances recombinant adeno-associated virus transduction efficiency".
Latest News
2024-01-08 08:47:00 - GlobeNewsWire
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
2023-12-13 14:01:03 - Seeking Alpha
Altamira Therapeutics Ltd. (CYTO) Special Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Special Call December 11, 2023 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman and CEO Conference Call Participants Operator Good morning, and welcome to Altamira Therapeutics December 23, 2023 Investor Business Update Conference Call.
2023-11-27 08:48:59 - InvestorPlace
Why Is Altamira Therapeutics (CYTO) Stock Down 8% Today?
Altamira Therapeutics (NASDAQ: CYTO ) stock isn't doing so hot on Monday after the company was given a delisting notice last week. That delisting notice comes from the Listing Qualifications Department of the Nasdaq Exchange.
2023-11-20 10:17:26 - PennyStocks
Best Penny Stocks To Buy This Week? 4 To Watch Now
Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the “Magnificent Seven” could become a major catalyst.
2023-11-17 14:45:12 - InvestorPlace
Why Is Altamira Therapeutics (CYTO) Stock Up 160% Today?
Among the leading gainers in the market today, Altamira Therapeutics (NASDAQ: CYTO ) is certainly raising eyebrows. In earlier trading, shares of the biotech company focused on RNA-based therapeutics more than tripled.
2023-11-17 11:19:16 - PennyStocks
Penny Stocks To Buy? 4 Under $5 To Watch Right Now
When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.
2023-11-03 07:53:18 - InvestorPlace
Why Is Altamira Therapeutics (CYTO) Stock Up 28% Today?
Altamira Therapeutics (NASDAQ: CYTO ) stock is rising higher on Friday despite a lack of news from the biopharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
2023-09-12 12:15:23 - Seeking Alpha
Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2023 Earnings Conference Call September 12, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman & CEO Covadonga Paneda - Chief Operating Officer Conference Call Participants Operator Good morning, and welcome to the Altamira Therapeutics First Half 2023 Financial Results and Business Update Conference Call.
2023-08-23 08:47:00 - GlobeNewsWire
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.
2023-05-24 10:16:32 - PennyStocks
Best Penny Stocks Today? 3 Under $1 To Watch Now
If you're looking for the best penny stocks to buy today, you should be well-prepared to deal with high volatility. Whether it's the latest debt ceiling crisis, pandemic fear reemerging, today's Fed meeting minutes from May, or speeches by Janet Yellen and Federal Reserve members, there are plenty of headlines to contend with.